NCT01162889 - Study To Assess The Safety And Tolerability Of Increasing Single Doses Of ATR-107 (PF-05230900) In Healthy People | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions

Healthy

Interventions

DRUG

Placebo SC Injection

Single injection

DRUG

ATR-107 (PF-05230900) SC Injection

Single intravenous infusion, 60 minute duration

DRUG

ATR-107 (PF-05230900) SC Injection

Single subcutaneous injection

DRUG

ATR-107 (PF-05230900) SC Injection

Single subcutaneous injection

DRUG

ATR-107 (PF-05230900) SC Injection

Single subcutaneous injection

DRUG

ATR-107 (PF-05230900) SC Injection

Single subcutaneous injection

DRUG

ATR-107 (PF-05230900) IV Infusion

Single subcutaneous injection

DRUG

ATR-107 (PF-05230900) IV Infusion

Single intravenous infusion, 60 minute duration

DRUG

ATR-107 (PF-05230900) IV Infusion

Single intravenous infusion, 60 minute duration

DRUG

Placebo IV Infusion

Single intravenous infusion, 60 minute duration

DRUG

ATR-107 (PF-05230900) IV Infusion

Single intravenous infusion, 60 minute duration

Trial Locations (2)

66211

Pfizer Investigational Site, Overland Park

06511

Pfizer Investigational Site, New Haven